ROCKVILLE, Md., Aug. 29, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate the following upcoming investor conferences: Morgan Stanley 22nd Annual Global Healthcare Conference Fireside Chat: Thursday, September 5, 2024 at 5:35 p.m. ET Location: New York, NY Baird 2024 Global Healthcare Conference Fireside Chat: Wednesday, September 11, 2024 at 9:40 a.m. ET Location: New York, NY Live webcasts of the fireside chats at the Morgan Stanley and Baird conferences can be access ...

ROCKVILLE, Md., Aug. 27, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced data from its RGX-121 program for the treatment of mucopolysaccharidosis type II (MPS II), also known as Hunter syndrome, will be shared at the SSIEM 2024 Annual Symposium, taking place in Porto, Portugal from September 3-6, 2024. Abstract Title: CAMPSIITE™ phase I/II/III: Interim clinical update of RGX-121, an investigational gene therapy for treatment of neuronopathic mucopolysaccharidosis type II (MPS II) (PO-205) ...

ROCKVILLE, Md., Aug. 8, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference on Thursday, August 15, 2024. H.C. Wainwright 4th Annual Ophthalmology Virtual Conference Panel: The Evolving Therapeutic Landscape of AMD Date/Time: Thursday, August 15, 2024 at 9:00 a.m. EDT Location: Virtual A live webcast of the panel can be accessed in the Investors section of REGENXBIO's website at www.regenxbio.com. An archiv ...

Shares of Regenxbio (RGNX) have gained 17.7% over the past four weeks to close the last trading session at $12.51, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $41.83 indicates a potential upside of 234.4%. The average comprises 12 short-term price targets ranging from a low of $28 to a high of $61, with a standard deviation of $9.47. While the lowest estimate indicates an in ...

REGENXBIO Inc. (NASDAQ:RGNX) Q2 2024 Earnings Conference Call August 1, 2024 4:30 PM ET Company Participants Patrick Christmas - CLO Curran Simpson - President and CEO Steve Pakola - CMO Vit Vasista - CFO Conference Call Participants Gena Wang - Barclays Vikram Purohit - Morgan Stanley Paul Choi - Goldman Sachs Annabel Samimy - Stifel C.J. Yeh - Leerink Partners Luca Issi - RBC Brian Skorney - Baird Daniil Gataulin - Chardan Capital Markets Operator Welcome everyone to the Q2 2024 REGENXBIO's Earnings Confe ...

Regenxbio (RGNX) came out with a quarterly loss of $1.05 per share versus the Zacks Consensus Estimate of a loss of $1.29. This compares to loss of $1.66 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 18.60%. A quarter ago, it was expected that this biotechnology company would post a loss of $1.28 per share when it actually produced a loss of $1.38, delivering a surprise of -7.81%. Over the last four quarters, the company ha ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___ to ___ Commission File Number 001-37553 REGENXBIO Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 47-1851754 (State ...

EXHIBIT 99.1 REGENXBIO Reports Second Quarter 2024 Financial Results and Recent Operational Highlights • Company remains on track for its first BLA filing in 2024 and is accelerating progress toward pivotal trial initiation for Duchenne (H2 2024) and diabetic retinopathy (H1 2025) o New, positive data from Phase II AFFINITY DUCHENNE ®trial of RGX-202 demonstrates consistent high expression of microdystrophin across treated patients in all age groups o Successful End-of-Phase II meeting with FDA for RGX-202 ...

Robust microdystrophin expression observed in new data from pivotal dose Patients aged 5.8 and 8.5 years at dosing had expression levels at 77.2% and 46.5% of control, respectively Consistent high expression of microdystrophin across treated patients in all age groups continues to support plans for accelerated approval Expects to initiate pivotal trial in Q4 2024 ROCKVILLE, Md., Aug. 1, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today reported new, positive interim safety and efficacy data in the Ph ...

REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the development of AAV Therapeutics, an innovative class of gene therapy medicines. REGENXBIO is advancing a pipeline of AAV Therapeutics for retinal and rare diseases, including ABBV-RGX-314 for the treatment of wet AMD and diabetic retinopathy, being developed in collaboration with AbbVie, RGX-202 for the treatment of Duche ...